The NHS is restricting the use of cholinesterase inhibitors to those with moderate Alzheimer’s disease or worse. The efficacy data for mild dementia is minimal – with up to 30 to 50 percent showing no improvement.
ADVERTISEMENT
Get free updates delivered free to your inbox.
Search thousands of physician, PA, NP, and CRNA jobs now.
Comments are moderated before they are published. Please read the comment policy.
